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doi:10.1Objective: Lung transplantation has become accepted therapy for end-stage pulmonary disease. The objective
of this study was to review a single-institution experience of adult lung transplants.
Methods:We reviewed 1000 adult lung transplants that were performed at Washington University between July
1988 and January 2009.
Results: Transplants were performed for emphysema (52%), cystic fibrosis (18.2%), pulmonary fibrosis
(16.1%), and pulmonary vascular disease (7.2%). Overall recipient age was 48  13 years with an increase
from 43 12 years (July 1988–November 1993) to 50 14 years (June 2005–January 2009). Overall incidence
of primary graft dysfunction was 22.1%. Hospital mortality was higher for patients who had primary graft
dysfunction (primary graft dysfunction, 13.6%; no primary graft dysfunction, 4%; P<.001). Freedom from
bronchiolitis obliterans syndrome was 84% at 1 year, 38.2% at 5 years, and 12.2% at 10 years. Survival at
1, 5, 10, and 15 years was 84%, 56.4%, 32.2%, and 17.8%, respectively. Five-year survival improved from
49.6% (July 1988–November 1993) to 62.1% (October 2001–June 2005). Primary graft dysfunction was asso-
ciated with lower survival at 1, 5, and 10 years (primary graft dysfunction: 72.8%, 43.9%, and 18.7%,
respectively; no primary graft dysfunction: 87.1%, 59.8%, and 35.7%, respectively, P<.001) and lower rates
of freedom from bronchiolitis obliterans syndrome (primary graft dysfunction: 78%, 27.5%, and 8.5%, respec-
tively; no primary graft dysfunction: 85.4%, 40.7%, and 13.1%, respectively, P ¼ .007).
Conclusions: Five-year survival has improved over the study period, but long-term outcomes are limited by bron-
chiolitis obliterans syndrome. Primary graft dysfunction is associated with higher rates of bronchiolitis obliterans
syndrome and impaired short- and long-term survival. A better understanding of primary graft dysfunction and
bronchiolitis obliterans syndrome is critical to improve outcomes. (J Thorac Cardiovasc Surg 2011;141:215-22)T
XDuring the last 3 decades, lung transplantation has evolved
into established therapy for end-stage lung disease. The Reg-
istry of The International Society for Heart and Lung Trans-
plantation indicates that 2708 lung transplants were
performed worldwide in 2007.1 Despite changes in patient
selection, refinements in operative techniques, and improve-
ments in postoperative care, outcomes have remained worse
compared with other organ transplants. This field faces nu-
merous challenges, which include, but are not limited to,
a shortage of donor organs, a relatively high incidence of pri-
mary graft dysfunction (PGD), and a high rate of graft failure
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The Journal of Thoracic and Capreviously described the incidence and outcomes of compli-
cations in 706 adult and 277 pediatric lung transplants.2 The
current article reports our experience with 1000 adult lung
transplants that were performed at a single institution over
a period of more than 2 decades. We outline temporal devel-
opments in patient selection and outcomes, and specifically
examine the incidence of PGD and BOS.
MATERIALS AND METHODS
Patient Demographics
One thousand adult lung transplants were performed at Barnes-Jewish
Hospital between July 1988 and January 2009. Results were analyzed ret-
rospectively using a prospectively gathered database of our lung transplant
program. Permission for this study was obtained from The Washington
University in St Louis Institutional Review Board.
Table 1 shows demographic data for all patients. These data are broken
down into quintiles in Table 2. Mean recipient age was 47.8  12.9 years.
Therewas an increase in mean age from 43.4 12 years in the first quintile
(July 1988 to November 1993) to 50.1  14 years in the last quintile (June
2005 to January 2009). A total of 506 patients (50.6%) were male, and 494
patients (49.4%) were female. We performed bilateral lung transplants in
805 patients (80.5%) and single lung transplants in 186 patients (18.6%).
Six patients underwent combined heart–lung transplantation, and 3 patients
received bilateral lobar transplants. A total of 520 transplants (52%) were
performed for emphysema, 182 transplants (18.2%) were performed for
cystic fibrosis, 161 transplants (16.1%) were performed for pulmonary
fibrosis, 72 transplants (7.2%) were performed for pulmonary vascular
disease, 29 transplants (2.9%) were performed for bronchiectasis, 17rdiovascular Surgery c Volume 141, Number 1 215
Abbreviations and Acronyms
BOS ¼ bronchiolitis obliterans syndrome
COPD ¼ chronic obstructive pulmonary disease
DCD ¼ donation after cardiac death
PGD ¼ primary graft dysfunction
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Xtransplants (1.7%) were performed for lymphangioleiomyomatosis, and
16 transplants (1.6%) were performed for sarcoidosis. Over the study pe-
riod, there has been a marked decline in lung transplants performed for pul-
monary vascular disease (14.5% during the first quintile vs 1.5% during
the last quintile) and a substantial increase in transplants for pulmonary fi-
brosis (9.5% during the first quintile vs 31.5% during the last quintile). We
have also experienced a recent decline in transplants for emphysema
(39.5% during the last quintile vs 48.5%–66.5% during the previous 4
quintiles). Specifically, before implementation of the lung allocation score
in 2005, 42.9% of transplants were performed for chronic obstructive pul-
monary disease (COPD), 23.9% were performed for cystic fibrosis, and
14.7% were performed for pulmonary fibrosis. After introduction of the
lung allocation score, we experienced a proportional decrease in trans-
plants for COPD (30%) and cystic fibrosis (19.8%) concomitant with an
increase in transplants for pulmonary fibrosis (21.8%). The mean lung al-
location score at the time of transplantation was 33.5 for patients with
COPD, 45.8 for patients with cystic fibrosis, and 51.3 for patients with pul-
monary fibrosis. The mean time on thewaiting list was 510.3 326.4 days.
For all transplants, including those performed after implementation of the
lung allocation score, waiting periods were determined on the basis of the
time from listing for transplantation until the day of the procedure. From
the first to the third quintile the mean waiting period had steadily increased
from 203.8  145.2 days to 717.3  269.4 days. Over the most recent 2
quintiles, the mean time on the waiting list has progressively decreased
to 574.6  307 days.
Postoperative Management
The majority of recipients received either Atgam or an interleukin 2-re-
ceptor antagonist as induction therapy. Patients were maintained on triple-
drug immunosuppression consisting of steroids, a cell cycle inhibitor, and
a calcineurin inhibitor. All patients underwent routine postoperative sur-
veillance bronchoscopy, and maintenance immunosuppression was ad-
justed on the basis of these findings.
Statistical Analysis
Categoric data were compared with Fisher’s exact or chi-square tests,
and normally distributed continuous variables were compared with a 2-
tailed Student t test. Skewed data were compared with the Wilcoxon
rank-sum test. Rates for survival and freedom from BOS were calculated
using the Kaplan–Meier method. Data analysis was performed using
SPSS software (SPSS 11.0; SPSS Inc, Chicago, Ill).RESULTS
Survival
Sixty-one patients (6.1%) died during their initial hospi-
tal stay with a decline from 11% during the first quintile to
4.5% to 5% during the subsequent quintiles. Overall sur-
vival was 85%, 57.5%, 33.2%, and 18.3% at 1, 5, 10,
and 15 years, respectively (Figure 1, A). The median sur-
vival times were 4.5, 6.2, and 6.8 years for the first, second,
and third quintiles, respectively. We observed steady216 The Journal of Thoracic and Cardiovascular Surgimprovements in 3-year (67%, 69%, 72.5%, and 73%, re-
spectively) and 5-year survival over the first 4 quintiles
(48.5%, 57%, 58%, and 62.1%, respectively) and 10-
year survival over the first 3 quintiles (22.5%, 30.5%,
and 41.3%, respectively) (Figure 1, B). Although we ob-
served progressive improvements in 1-year survival during
the first 4 quintiles (79%, 83%, 86%, and 88%, respec-
tively), there was a modest decrease in 1-year survival to
84.4% during the fifth quintile. Bilateral lung transplanta-
tion was associated with better survival than single lung
transplantation at all time points examined (1 year:
85.7% vs 82.1%; 3 years: 72.1% vs 68.2%; 5 years
60.1% vs 47.6%; 10 years 37.3% vs 20.1%). Survival
was 61.6% and 38.4% for patients with emphysema who
received bilateral lung transplants and 58.9% and 36.7%
for patients with pulmonary fibrosis at 5 and 10 years,
respectively, which was significantly higher than those for
recipients of single lungs for both disease processes (em-
physema: 43.2% and 13%; pulmonary fibrosis: 44.9%
and 20.8% at 5 and 10 years, respectively.)
Primary Graft Dysfunction
A total of 221 patients (22.1%) had PGD. Notably, we
did not observe marked changes in the incidence of this
complication over our study period (Figure 2, A). PGD
had a significant adverse effect on both short- and long-
term survival. The hospital mortality for lung transplant re-
cipients who had PGD was significantly higher than that for
patients who did not have this complication (13.6% vs 4%,
P<.001). Survival at 1, 5, and 10 years for patients whose
course was complicated by PGD was 72.8%, 43.9%, and
18.7%, respectively (Figure 2, B). Survival at these time
points was significantly higher for those recipients who
did not experience PGD (87.1%, 59.8%, 35.7%, respec-
tively; P<.001). Eleven patients underwent retransplanta-
tion for PGD.
Bronchiolitis Obliterans Syndrome
Freedom rates from BOS were 84%, 54.3%, 38.2%, and
12.2% at 1, 3, 5, and 10 years, respectively (Figure 3, A).
The median time from the transplant procedure to the point
when BOS was diagnosed was 3.4 years; 81.9% of recipi-
ents in the first quintile did not have BOS at 1 year, which
was comparable to the rates for patients in the subsequent
4 quintiles. However, for patients in the first quintile, we ob-
served markedly lower rates of freedom from BOS at
3 (39.6%) and 5 (24.3%) years when compared with the
remainder of the patient cohort (Figure 3, B). Nine lung
retransplantations were performed for patients with BOS.
PGD was also associated with lower rates of freedom
from BOS at all time points examined (Figure 3, C). In the
cohort of patients who had PGD, the rates of freedom
from BOS were 78%, 27.5%, and 8.5% at 1, 5, and 10
years, respectively. Alternatively, 85.4%, 40.7%, andery c January 2011
TABLE 1. Recipient demographic data
Age (y) 47.8  12.9
51 (IQR: 39–58)
Gender (male) 506 (50.6%)
Diagnosis
Emphysema 520 (52.0%)
Cystic fibrosis 182 (18.2%)
Pulmonary vascular disease (PPH,
Eisenmenger’s, CHD-PH)
72 (7.2%)
IPF/PF 161 (16.1%)
Sarcoid 16 (1.6%)
Bronchiectasis 29 (2.9%)
LAM 17 (1.7%)
Other pulmonary disease 3 (0.3%)
Time on the waiting list (d) 510.3  326.4
488 (IQR: 342 – 631)
Type of transplant performed
Bilateral 805 (80.5%)
Single 186 (18.6%)
Heart/lung 6 (0.6%)
Bilateral lobar 3 (0.3%)
Ischemic time (min)
First lung 246.7  57.9
Second lung 335.3  69.3
Length of mechanical ventilation (median, d) 2 (IQR: 1–3)
Length of stay in ICU (median, d) 3 (IQR: 2–5)
Length of stay in hospital (median, d) 15 (IQR: 11–23)
PGD 221 (22.1%)
PTLD 55 (5.5%)
Hospital mortality 61 (6.1%)
IQR, Interquartile range (25%–75%); PPH, primary pulmonary hypertension; CHD-
PH, congestive heart disease-pulmonary hypertension; IPF/PF, idiopathic pulmonary
fibrosis/pulmonary fibrosis; LAM, lymphangioleiomyomatosis; ICU, intensive care
unit; PTLD, posttransplant lymphoproliferative disorder.
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X13.1% of transplant recipients who did not have this compli-
cation were free fromBOS at the same time points (P<.01).
Length of Stay
The median length of mechanical ventilation was 2 days,
and themedian length of stay in the intensive care unit was 3
days with no marked changes in these parameters over the
study period. The median length of stay in the hospital
was 15 days. This reflects a decrease from 22 days during
the first quintile to 15 days for all subsequent quintiles.
DISCUSSION
This article represents the largest single-institution series
of adult lung transplants that has been reported to date. The
patients presented underwent transplantation during a pe-
riod of more than 2 decades. Our group previously reviewed
our experience with 277 pediatric and 706 adult lung recip-
ients. The current report focuses on adult recipients only. A
large portion of the 294 adult patients who have been added
to the current analysis underwent transplantation since the
implementation of the lung allocation score, reflecting
a marked change in the composition of the recipient popu-The Journal of Thoracic and Calation. Several observations in our series highlight recent
trends, such as the use of more marginal donors, and current
challenges of lung transplantation, such as persistently
high rates of PGD despite refinements in preservation
solutions.
Survival at 1, 3, 5, and 10 years has consistently im-
proved during the first 4 quintiles. Improvements in late
survival are likely to be in large part due to improvements
in early survival. Factors that may have contributed to im-
provements in early survival and especially to the decrease
in hospital mortality after the first quintile are refinements
in perioperative management. Notably, the rates of freedom
from BOS are markedly lower for patients in the first
quintile than for those who underwent transplantation
thereafter, suggesting that better management of early com-
plications, such as PGD, acute rejection, and infections,
which are known risk factors for BOS, has played a role
in improvements in long-term survival after the first quin-
tile. Moreover, with the exception of the third quintile,
we have observed a progressive decline in the incidence
of posttransplant lymphoproliferative disorder (Tables 1
and 2), which also may have contributed to improvements
in overall survival after the first quintile. Of note, starting in
the third quintile, a team of critical care physicians has been
involved in the management of lung transplant recipients
during their stay in the intensive care unit. Changes in
our immunosuppressive regimen are likely to have contrib-
uted to improvements in long-term outcomes. This is illus-
trated by the results of a study that was performed during
the third quintile, in which maintenance immunosuppres-
sion with tacrolimus yielded superior results compared
with cyclosporine.3 Also, during the third quintile, our in-
stitution started using new treatment strategies, such as azi-
thromycin and photopheresis, for patients with BOS.4,5
Such interventions are also likely to have contributed to
improvements in overall survival. Collectively, our results
indicate that the increase in overall survival is in large
part due to improvements in short-term survival and prob-
ably to a lesser extent more effective management of long-
term complications. Notably, a recent review of the registry
of the International Society for Heart and Lung Transplan-
tation has reached analogous conclusions.1 Compared with
the fourth quintile, there was a decline in both 1- and 3-year
survival during the last quintile, which can at least in part be
attributed to a change in the recipient population secondary
to the implementation of the lung allocation score and the
acceptance of more marginal donors.
We prefer to perform bilateral rather than single lung
transplants for patients with both suppurative and nonsup-
purative lung diseases, such as emphysema or fibrosis. We
previously reported that bilateral lung transplantation for
patients with COPD is associated with better long-term sur-
vival than single lung transplantation, a finding now corrob-
orated by others.6,7 Notably, improved long-term survivalrdiovascular Surgery c Volume 141, Number 1 217
TABLE 2. Recipient demographic data stratified by quintiles
Quintile 1 N ¼ 200 Quintile 2 N ¼ 200 Quintile 3 N ¼ 200 Quintile 4 N ¼ 200 Quintile 5 N ¼ 200
Date range 07/88–11/93 11/93–01/98 01/98–10/01 10/01–06/05 06/05–1/09
Age (y) 43.4  12.0 46.7  12.1 50.5  11.0 48.6  14.1 50.1  14.0
Gender (male) 93 (46.5%) 101 (50.5%) 102 (51.0%) 100 (50.0%) 110 (55.0%)
Diagnosis
Emphysema 108 (54.0%) 97 (48.5%) 133 (66.5%) 103 (51.5%) 79 (39.5%)
Cystic fibrosis 33 (16.5%) 31 (15.5%) 29 (14.5%) 51 (25.5%) 38 (19.0%)
Pulmonary vascular disease 29 (14.5%) 23 (11.5%) 7 (3.5%) 10 (5.0%) 3 (1.5%)
IPF/PF 19 (9.5%) 27 (13.5%) 21 (10.5%) 31 (15.5%) 63 (31.5%)
Sarcoid 2 (1.0%) 2 (1.0%) 2 (1.0%) 2 (1.0%) 8 (4.0%)
Bronchiectasis 5 (2.5%) 13 (6.5%) 2 (1.0%) 2 (1.0%) 7 (3.5%)
LAM 3 (1.5%) 7 (3.5%) 5 (2.5%) 1 (0.5%) 1 (0.5%)
Other pulmonary disease 1 (0.5%) 0 1 (0.5%) 0 1 (0.5%)
Time on the waiting list (d) 203.8  145.2 530.1  201.7 717.3  269.4 610.1  437.8 574.6  307.0
Type of transplant performed
Bilateral 101 (50.5%) 147 (73.5%) 178 (89.0%) 190 (96.0%) 189 (94.5%)
Single 99 (49.5%) 51 (25.5%) 20 (10.0%) 6 (2.0%) 10 (5.0%)
Heart/lung 0 2 (1.0%) 2 (1.0%) 1 (0.5%) 1 (0.5%)
Bilateral lobar 0 0 0 3 (1.5%) 0
Length of mechanical
ventilation
3 (IQR: 2–5) 2 (IQR: 1–4) 1 (IQR: 1–2) 1 (IQR: 1–3) 2 (IQR: 1–7)
Length of stay in ICU 4 (IQR: 3–6) 3 (IQR: 2–6) 2 (IQR: 2–4) 3 (IQR: 2–5) 4 (IQR: 2–10)
Length of stay in hospital 22 (IQR: 18–29) 15 (IQR: 11–23) 15 (IQR: 11–23) 15 (IQR: 11–23) 15 (IQR: 11–23)
PGD 46 (23.0%) 39 (19.5%) 37 (18.5%) 52 (26.0%) 47 (23.5%)
PTLD 19 (9.5%) 9 (4.5%) 13 (6.5%) 8 (4%) 6 (3%)
Hospital mortality 22 (11.0%) 10 (5.0%) 9 (4.5%) 10 (5.0%) 10 (5.0%)
IPF/PF, Idiopathic pulmonary fibrosis/pulmonary fibrosis; LAM, lymphangioleiomyomatosis; ICU, intensive care unit; PTLD, posttransplant lymphoproliferative disorder; IQR,
interquartile range.
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Xafter bilateral lung transplantation in this patient population
may in part be due to lower rates of BOS.8 Notably, a recent
analysis of the United Network for Organ Sharing database
showed that survival after bilateral and single lung trans-
plantation was comparable in patients aged 60 years or
more.9 The choice of single lung transplantation for non-
suppurative lung diseases is often guided by the shortage
of donor organs and the desire to perform transplantation
in 2 recipients rather than 1 recipient.10 Because advances
such as ex vivo reconditioning will probably expand the
availability of donor lungs in the future, bilateral lung trans-
plantation is likely to be more universally used.
One of the most striking findings is the impact that PGD
has on both short- and long-term outcomes. PGD after
lung transplantation, formerly referred to as reimplantation
response, is widely perceived to be a consequence of ische-
mia–reperfusion injury. Both experimental and clinical stud-
ies have suggested that compared with other organs, lungs
are particularly susceptible to ischemia–reperfusion injury.11
Numerous experimental studies have shown that extracellu-
lar solutions are superior for lung preservation when
compared with intracellular solutions.12 Although many
clinical studies have confirmed these observations, some
studies have yielded conflicting results.13,14 Our group
switched from intracellular to extracellular solutions for
lung preservation in May 2001. Nevertheless, the rates of218 The Journal of Thoracic and Cardiovascular SurgPGD have remained stable over our study period. Notably,
a recent study found that a non-COPD recipient diagnosis
is a risk factor for the development of PGD.15 Therefore,
a progressive decrease in transplants for COPD from
66.5% during the third quintile to 39.5% during the fifth
quintile may have contributed to steady rates of PGD despite
improvements in lung preservation.Another potential reason
for the persistently high incidence of PGD is a progressive
shift toward acceptance of marginal donors in our program.
To this end, Whitson and colleagues15 have identified donor
age and donor smoking history as significant risk factors for
PGD. An important consideration in this context is that the
relative shortage of donor lungs has led to the use of donation
after cardiac death (DCD), as well as ex vivo perfusion and
reconditioning of marginal lungs. Although there are no de-
finitive data available on whether the use of DCD is associ-
ated with a higher incidence of PGD, the period of relative
warm ischemia inherent to this procedure poses a potential
concern. In our own experience with 11 lung transplants,
for which we used DCD, the incidence of grade 3 PGD
was 36%, which was twice as high as in patients who re-
ceived lungs from brain-dead donors during the same time
period.16 Our findings contrast with those of Erasmus and
colleagues,17 who recently reviewed outcomes in 21 patients
receiving lungs from non–heart-beating donors. Rates of
PGD in this cohort were equivalent to those of a controlery c January 2011
FIGURE 1. A, Survival after lung transplantation (n¼ 1000). B, Survival
after lung transplantation stratified by quintile.
FIGURE 2. A, Incidence of PGD presented for individual quintiles. B,
Survival after lung transplantation stratified by PGD. BOS, Bronchiolitis
obliterans syndrome; PGD, primary graft dysfunction.
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Xgroup of 77 patients who received lungs from heart-beating
donors.Moreover, in their series therewere no differences in
2-year survival between lung recipients who received organs
from heart-beating or non–heart-beating donors. Recent
work from thegroup at TorontoGeneralHospital has demon-
strated that treatment of human lungswith an adenoviral vec-
tor encoding interleukin-10 during a period of ex vivo
perfusion leads to functional improvement.18 This technique
holds great promise to reduce rates of PGD asmore insight is
gained into its pathogenesis.
The persistently high rates of PGD affecting our lung
transplant recipients is an alarming fact clearly indicating
that research efforts need to be directed toward studies in
this field that would provide mechanistic insight into its
pathogenesis. Our study confirms that PGD adversely af-
fects early outcomes as evidenced by increased hospital
mortality and inferior survival at 1 year. In addition, 10-
year survival in patients with PGD is approximately 50%
lower than those of recipients without this complication.
Our findings support and extend previous reports from our
institution that have examined long-term consequences of
PGD. In a retrospective analysis of 334 adult lung transplant
recipients, Daud and colleagues19 found that all grades
of PGD assessed immediately after transplantation were
associated with an increased risk of developing BOS inde-The Journal of Thoracic and Capendently of other factors, including acute rejection, lym-
phocytic bronchiolitis, and respiratory viral infections.
Huang and colleagues20 followed up on this observation
and reported that in the same cohort of patients all grades
of PGD at 24, 48, and 72 hours after transplantation are sig-
nificant risk factors for the development of BOS.20
Our case series clearly illustrates that BOS, widely con-
sidered to represent a manifestation of chronic allograft re-
jection, remains the Achilles’ heel of lung transplantation.
Strikingly, the rates of freedom from BOS at 1 and 3 years
have remained virtually unchanged throughout the duration
of our experience. Clinical studies have suggested that both
alloimmune events, such as acute rejection and lymphocytic
bronchiolitis, as well as non-alloimmune factors, such as
PGD, gastroesophageal reflux, and respiratory viral infec-
tions, contribute to the development of this condition.19
Our findings that patients who had PGD had higher rates
of BOS support an association between these 2 conditions.
It is intriguing that a clinical study from Duke University
demonstrated that lung recipients with Toll-like receptor 4
polymorphisms that are associatedwith hyporesponsiveness
to endotoxin had fewer episodes of acute rejection andrdiovascular Surgery c Volume 141, Number 1 219
FIGURE 3. A, Freedom rates from BOS (n ¼ 1000). B, Freedom rates
from BOS stratified by era. C, Freedom rates from BOS stratified by
PGD. BOS, Bronchiolitis obliterans syndrome; PGD, primary graft dys-
function.
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Xa trend toward increased BOS-free survival.21 Endogenous
ligands that are released during ischemia–reperfusion injury
can signal through Toll-like receptor 4 and ischemia–reper-
fusion injury is attenuated in Toll-like receptor 4-deficient
animals, raising the possibility that innate immune receptors
provide a link between PGD and graft rejection.22,23
The increasing number of patients dying on the waiting
list, in large part resulting from a relative shortage of donor
organs, was one of the main driving forces to change the
allocation system of lungs. An important criticism of the220 The Journal of Thoracic and Cardiovascular Surgold allocation system that was based primarily on time ac-
crual on the waiting list was that many patients were listed
for lung transplantation during relatively early stages of
their disease, which resulted in the death of more critically
ill patients. To this end, the lung allocation score was imple-
mented in 2005, which took into consideration the probabil-
ity of survival on thewaiting list and predicted survival after
pulmonary transplantation. On the basis of data from 5 cen-
ters, including our own, Kozower and colleagues24 reported
short-term outcomes of the impact of the lung allocation
score. There has been a relative increase in transplants for
pulmonary fibrosis and a relative decrease in transplants
for COPD and cystic fibrosis since the introduction of the
lung allocation score. The time on the waiting list decreased
significantly from 681 to 446 days, and the number of pa-
tients on the waiting list has decreased substantially.25
Not surprisingly, the number of retransplantations has dra-
matically increased because critically ill patients who
have previously received lung grafts can have high alloca-
tion scores. Although higher allocation scores at the time
of transplantation are associated with worse outcomes,
there exists some controversy about the impact of the
lung allocation score on 1-year survival.24,26 At our
center, the 1- and 3-year survivals have decreased during
the fifth quintile, which temporally coincides with the
implementation of the lung allocation score. Clearly,
long-term data are necessary to better define the conse-
quences of the lung allocation score.CONCLUSIONS
Although we have observed improvements in long-term
survival since the inception of our program, many
challenges remain in lung transplantation. The prospect of
reconditioning marginal lungs holds great promise to
expand the donor pool. It also opens an exciting avenue
into therapeutic interventions before implantation. Ad-
vances in treatment and prevention of PGD and graft rejec-
tion, 2 of the main obstacles to long-term success, will
undoubtedly depend on basic science investigations. Dissec-
tion of cellular and molecular mechanisms that contribute
to complications in human lung recipients will be facilitated
by recently developed murine models and existing preclini-
cal large animal models of lung transplantation.27-29References
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Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dan, congrat-
ulations on an excellent presentation. I would like to congratulate
your whole group. Certainly Joel Cooper and Alec Patterson have
led the world in making lung transplantation a clinical reality.
What you have demonstrated is that lung transplantation can be
made a more routine operation, and you’ve provided a benchmark
in your results.
You talked about the incidence of PGD and its effect on chronic
graft dysfunction or BOS. Did you actually look at the grades of
PGD? Is it just the grade 3 PGDs that give you the poorer long-
term outcome or is it any PGD?
Dr Kreisel. There were 2 articles published from our institution
over the last few years, one by Daud and colleagues a few years
back in which he showed that all grades of PGD immediately post-
operatively were independent risk factors for the development of
BOS, and Huang and colleagues recently followed up in an article
published in the American Journal of Transplantation in which he
showed that all grades of PGD at 24, 48, and 72 hours postopera-
tively were independent risk factors for the development of BOS.
So at least in our institution, all grades seemed to correlate with the
development of late graft dysfunction.
Dr Keshavjee. I think that is an important point, because one of
the concepts that has emerged in recent years is our understanding
that late graft dysfunction is not just allograft rejection, but a mul-
tifactorial process that relates to the early events as well.
My second question, you mentioned your experience with DCD
lungs and the fact that the incidence of severe grade 3 PGD was
35%, or twice that in your brain-dead donor lungs. Currently,
many people in the field have gone so far as to say that DCD lungs
are equivalent donor lungs, or some even say that they are superior
to brain-dead donor lungs. What have you learned from your expe-
rience that you can share with us in terms of what you define as
a high-risk DCD lung?
Dr Kreisel. I don’t have a great answer for this. Our series that
we published last year included only 11 or 14 DCD donors with
a high incidence of PGD, and I don’t have the data on whether
the ischemic times were very long or whether there were any other
factors, and I know that other studies do not mirror this experience.
I think that as we accumulate more numbers, we may get a better
idea. But along the same lines, there are many events in the donor,
except for the DCD aspect, that we just don’t understand what
predicts the development of PGD, and there is a lot of work to
be done there. So I think it was just a small series, and I don’t
know whether it’s reflective of what we will see in the future.
DrKeshavjee. The introduction of the lung allocation score cer-
tainly has affected your program and changed the type of patients
who undergo transplantation. The indication for transplant diagno-
sis has shifted from predominantly emphysema to more idiopathic
pulmonary fibrosis and higher scoring patients, but I was surprisedrdiovascular Surgery c Volume 141, Number 1 221
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Xto see that it hasn’t affected your waiting time, with your waiting
time still being more than 1.5 years. I thought that the system
was going to help to sort that out in the United States. Do you
have any insights as to why it has not affected your program?
Dr Kreisel. It has affected the program. The mean waiting time
decreased from in excess of 600 days to 550 days, but why it is sig-
nificantly longer than, for example, what you experience, I don’t
have an answer for that.
Dr Keshavjee.Well, just for the information of the audience, in
the United States the waiting time varies from less than 1 month to
more than 1.5 years across the country, so it does reflect that we
haven’t totally fixed the problem with the lung allocation score.
Dr Raphael Bueno (Boston, Mass). You demonstrated that
there are different overall survivals based on the era, there was
a difference in the survival between a double and a single lung,
and there was a change when you moved more to double lungs,
if I recall. Did you take that into consideration when you showed
a difference in survival? You showed a 10-year follow up as op-
posed to a 15-year follow-up on that slide.
Dr Kreisel. I’m afraid I don’t understand your question.
Dr Bueno. Was there any time bias that could have explained
some of the differences you saw in this particular series in the sur-
vival long range between a double and a single lung transplant?
DrKreisel.No. I think the survival difference between bilateral
and single lung transplantation for emphysema and fibrosis is seen
by virtually all centers, and the centers that do not do bilateral trans-
plants do it according to availability of donor organs. So we have
seen a consistently better survival with bilateral lung transplants
than with single lung transplants, and I know of studies from
Duke and Toronto in which bilateral lung transplants were also cor-
related with lower incidence of BOS, which may provide an expla-
nation in addition to just having larger lungmass and lung capacity.
Dr Dirk Van Raemdonck (Leuven, Belgium). I’m interested in
knowing your strategies and techniques for extracorporeal support
if needed during transplantation. Has that changed over the years?
Dr Kreisel. You mean implementation of extracorporeal
membrane oxygenation if..
Dr Shrager. The use of bypass.
Dr Kreisel.We do not use elective bypass. The implementation
of cardiopulmonary bypass is either done on the basis of parame-
ters during the implantation or on preoperative parameters, but
there is no planned use of cardiopulmonary bypass at our center.
Dr Van Raemdonck. And are you using central cannulation or
peripheral?
Dr Kreisel. Central cannulation.
Dr Stephen Cassivi (Rochester, Minn). Dan, this is excellent.
You are part of a great team, obviously. I have 2 questions.
One, with regard to the PGD, you were stating in your presen-
tation that it has an effect on long-term and you showed us a curve.
What I saw was that the curve drops early, as we would expect, but
the curve later on is parallel. I don’t know whether that long-term
survival is just because they have such poor short-term survival.
Did you do anything to statistically show that after that, the condi-
tional survival is worse?
DrKreisel. I don’t think we did that analysis, but what I can tell
you is that at least in the experimental setting we have evidence
that those early events alter the adaptive immune response, and222 The Journal of Thoracic and Cardiovascular Surgthe adaptive immune response is changed at late time points in an-
imal models based on early PGD due to some interplay between
innate and adaptive immune responses. So I don’t think it’s just
a matter of the early mortality as to why we see late failure in pa-
tients who had PGD. I think there is obviously an early drop-off.
Dr Cassivi. I think you’re right, and intuitively we would think
that’s the same, but it might be interesting to look at the conditional
survival.
My second question is with regard to the lung allocation score
and how that has changed, and we see the drop-off at your institu-
tion, just like at ours and others, in thosewith COPD and how there
is a preference for the diseases other than COPD. In the recent his-
tory, have you noticed an increase in your wait-list mortality for the
patients with COPD?
Dr Kreisel. I don’t have the data. I do not think we have had an
increased mortality for patients with COPD, but I don’t have that
data.
Dr Daniel Mason (Cleveland, Ohio). I was a little surprised
that among 1000 transplants, only 20 were retransplants, and I
think only a handful of those were for BOS, and obviously there
is a lot of BOS out there. I was just curious about the Washington
University philosophy on retransplant and who is a candidate for
retransplant.
Dr Kreisel. Well, we list the patients with BOS for retrans-
plants. Why the number is so low, I don’t know. Recently we
started doing some photopheresis for BOS with some mild
improvement in outcomes, but I guess..
Dr Sugarbaker. The question is who would you consider for
a retransplant given the higher operative mortality and the lower
overall survival? Are all patients considered for retransplant
should they have graft failure early? How far out do you let
them go? Are there any issues around that that you could eluci-
date?
DrKreisel. I don’t know exactly why we haven’t done more re-
transplants. We certainly have a lot of patients with BOS listed for
retransplants. I don’t have an answer as to why the number has
been relatively low.
Dr Marcelo Cypel (Toronto, Ontario, Canada). Dan, that was
a nice presentation.
Do you have any numbers on PGD3 requiring extracorporeal
membrane oxygenation, and what were the outcomes of those
patients who underwent..
Dr Kreisel. I don’t have those numbers of how many patients
required it.
Dr Antoon Lerut (Leuven, Belgium). Over the recent years,
there has been a focus of interest on the relation between reflux
and BOS. Have you seen in your last cohort of patients an impact
of your antireflux therapy, whether it’s medical or surgical, on the
incidence of BOS and did it made a difference?
Dr Kreisel. We haven’t analyzed this specifically, as far as I
know, but we have been far more liberal offering fundoplications
to patients on the waiting list and early fundoplications in patients
who underwent lung transplantation.
Dr Lerut. Can you give us an idea about the fraction of patients
who are receiving an antireflux operation nowadays?
Dr Kreisel. I don’t know the exact number, but we have been
fairly liberal with that.ery c January 2011
